Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.

@article{Flaker1999PravastatinPC,
  title={Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.},
  author={Greg C. Flaker and J. Wayne Warnica and Frank M. Sacks and Lemuel A. Moye and Barry R. Davis and Jean Lucien Rouleau and R R Webel and Marc Pfeffer and Eugene Braunwald},
  journal={Journal of the American College of Cardiology},
  year={1999},
  volume={34 1},
  pages={106-12}
}
OBJECTIVES This analysis was carried out to determine if revascularized patients derive benefit from the 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pravastatin. BACKGROUND The HMG-CoA reductase inhibitors result in substantial reductions in serum cholesterol and stabilization of atherosclerotic plaques in patients with coronary artery disease. METHODS Pravastatin was found to reduce clinical cardiovascular events in the Cholesterol and Recurrent Events (CARE) trial… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

13-year follow-up of the German angioplasty bypass surgery investigation.

European heart journal • 2005
View 6 Excerpts
Highly Influenced

Simvastatin exerts favourable effects on neointimal formation in a mouse model of vein graft.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery • 2011

Applications of statins in cardiothoracic surgery: more than just lipid-lowering.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…